Quantum Biopharma (QNTM) Non-Current Assets (2018 - 2026)

Quantum Biopharma has disclosed Non-Current Assets across 9 years of filings, most recently posting $4.6 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $4.6 million, down 7.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (up 267.26% YoY), and the FY2023 annual result was $5.5 million, down 58.24% from the prior year.
• Non-Current Assets came in at $4.6 million for Q1 2026 at Quantum Biopharma, down from $4.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $13.1 million in Q4 2022 to a low of $4.6 million in Q1 2026.
• The 5-year median for Non-Current Assets is $5.1 million (2024), against an average of $6.0 million.
• Across the five-year window, Non-Current Assets tumbled 58.24% in 2023 and dropped 5.2% in 2025, its largest moves.
• Quantum Biopharma's Non-Current Assets stood at $13.1 million in 2022, then sank by 58.24% to $5.5 million in 2023, then decreased by 5.45% to $5.2 million in 2024, then retreated by 7.2% to $4.8 million in 2025, then slipped by 5.26% to $4.6 million in 2026.
• The last three Non-Current Assets figures came in at $4.6 million (Q1 2026), $4.8 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.